The MHRA is coordinating a three year EU-wide pharmacovigilance project to help member states meet the requirements of the new pharmacovigilance legislation. This ‘Joint Action’ is called Strengthening Collaboration for Operating Pharmacovigilance in Europe (SCOPE).

 

The key objective of SCOPE is to enable the National Competent Authorities in member states to move from implementation of the requirements of the new pharmacovigilance legislation to truly operating those requirements to the highest possible standards against agreed benchmarks and best practice.

 

The MHRA received cheaper viagra official confirmation in early November that the European Agency for Health and Consumers (EAHC), an executive agency of the European Commission, had approved funding for SCOPE. To formally launch SCOPE the MHRA arranged a workshop held at the EAHC in Luxembourg on 18 November 2013 which was attended by 40 delegates from 26 countries and institutions. The workshop provided an excellent opportunity to discuss topics such as adverse drug reaction reporting, signal detection and risk communications to inform, enthuse, and motivate the participating member states.

 

Further updates on SCOPE will be provided as the Joint Action progresses and a SCOPE website will be launched in early 2014. More information on Joint Actions can be found on the European Commission website: Call 2013: Joint action (external link)

 

Posted on the UK MHRA website on 28 November 2013